The value of platelet-rich plasma in women with previous implantation failure: a systematic review and meta-analysis

ObjectiveTo assess the value of intrauterine PRP to improve IVF outcome in women with previous implantation failure.MethodsScreening of Pubmed, Web of Science, and other databases from inception to August 2022 using the keywords related to platelet-rich plasma OR PRP AND IVF implantation failure. Twenty-nine studies (3308 participants) were included in our analysis, 13 were RCTs, 6 were prospective cohorts, 4 were prospective single arm, and 6 were retrospective analyses. Extracted data included settings of the study, study type, sample size, participants' characteristics, route, volume, timing of PRP administration, and outcome parameters.ResultsImplantation rate was reported in 6 RCTs (886 participants) and 4 non-RCTs (732 participants). The odds ratio (OR) effect estimate was 2.62 and 2.06, with 95% CI of 1.83, 3.76, and 1.03-4.11, respectively. Endometrial thickness was compared in 4 RCTs (307 participants) and 9 non-RCTs (675 participants), which showed a mean difference of 0.93 and 1.16, with 0.59-1.27 and 0.68-1.65 95% CI, respectively.ConclusionPRP administration improves implantation, clinical pregnancy, chemical pregnancy, ongoing pregnancy, live birth rates, and endometrial thickness in women with previous implantation failure.

Automated summary

This study aims to assess the value of intrauterine platelet-rich plasma (PRP) in improving IVF outcomes in women with previous implantation failure. A total of 29 studies involving 3308 participants were included in the analysis. The results showed that PRP administration improves implantation rate, clinical pregnancy rate, chemical pregnancy rate, ongoing pregnancy rate, live birth rate, and endometrial thickness.